Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

MLA

Lindemann, Kristina, et al. Examestane in Advanced or Recurrent Endometrial Carcinoma: A Prospective Phase II Study by the Nordic Society of Gynecologic Oncology (NSGO). 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233364719&authtype=sso&custid=ns315887.

APA

Lindemann, K., Malander, S., Christensen, R. D., Mirza, M. R., Kristensen, G. B., Åvall-Lundqvist, E., Vergote, I., Rosenberg, P., Boman, K., & Nordstrom, B. (2014). Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).

Chicago

Lindemann, Kristina, Susanne Malander, Rene D. Christensen, Mansoor R. Mirza, Gunnar B. Kristensen, Elisabeth Åvall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman, and Britta Nordstrom. 2014. “Examestane in Advanced or Recurrent Endometrial Carcinoma: A Prospective Phase II Study by the Nordic Society of Gynecologic Oncology (NSGO).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233364719&authtype=sso&custid=ns315887.